Profile data is unavailable for this security.
About the company
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
- Revenue in INR (TTM)17.55bn
- Net income in INR986.27m
- Incorporated1984
- Employees1.81k
- LocationMorepen Laboratories LtdVillage Malkumajra, Nalagarh Road,BaddiGURGAON 122016IndiaIND
- Phone+91 1 244892000
- Fax+91 1 123722422
- Websitehttps://www.morepen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syncom Formulations (India) Ltd | 5.15bn | 630.52m | 13.47bn | 554.00 | 20.77 | 3.56 | 19.71 | 2.62 | 0.69 | 0.69 | 5.56 | 4.03 | 1.24 | 8.89 | 5.41 | 9,296,547.00 | 15.22 | 8.56 | 17.65 | 11.58 | 36.52 | 34.81 | 12.24 | 10.15 | 4.24 | 73.92 | 0.0018 | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 13.71bn | 456.00 | 38.76 | -- | 25.76 | 3.07 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Beta Drugs Ltd | 3.86bn | 464.68m | 14.26bn | 399.00 | 20.26 | 6.45 | 23.28 | 3.70 | 69.72 | 65.19 | 509.33 | 218.94 | 0.986 | 3.64 | 3.48 | 9,665,303.00 | 11.88 | 15.08 | 16.29 | 21.53 | 39.79 | 40.30 | 12.05 | 12.72 | 2.45 | 5.13 | 0.3974 | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Amrutanjan Health Care Ltd | 4.88bn | 569.03m | 18.29bn | 631.00 | 32.14 | -- | 28.92 | 3.75 | 19.68 | 19.68 | 168.85 | -- | -- | -- | -- | 7,736,897.00 | -- | 15.84 | -- | 19.67 | 50.87 | 52.17 | 11.66 | 13.26 | -- | 319.69 | -- | 19.82 | 7.26 | 11.56 | 13.03 | 15.17 | 69.46 | 26.76 |
| Windlas Biotech Ltd | 8.30bn | 673.21m | 18.37bn | 1.35k | 27.41 | 3.42 | 18.81 | 2.21 | 31.79 | 31.79 | 392.02 | 254.82 | 1.06 | 6.73 | 4.32 | 6,167,994.00 | 8.62 | 8.65 | 13.24 | 11.81 | 38.24 | 34.09 | 8.11 | 7.70 | 1.80 | 15.42 | 0.0552 | 18.33 | 20.43 | 18.24 | 4.82 | 30.34 | 27.99 | -- |
| Indoco Remedies Ltd | 17.58bn | -1.14bn | 18.91bn | 6.05k | -- | -- | 295.94 | 1.08 | -12.52 | -12.52 | 197.86 | -- | -- | -- | -- | 2,905,519.00 | -- | 4.84 | -- | 6.87 | 71.18 | 65.70 | -6.62 | 5.16 | -- | -0.3334 | -- | 17.11 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
| Solara Active Pharma Sciences Ltd | 12.06bn | 64.10m | 21.13bn | 1.78k | 398.88 | 1.83 | 20.45 | 1.75 | 1.20 | 1.20 | 325.96 | 261.13 | 0.5263 | 1.68 | 3.32 | 6,794,423.00 | 0.2797 | -3.27 | 0.4821 | -5.35 | 54.11 | 39.95 | 0.5315 | -6.17 | 0.4929 | 0.9751 | 0.3394 | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Bliss GVS Pharma Ltd | 8.60bn | 1.10bn | 21.54bn | 966.00 | 19.74 | 1.90 | 14.61 | 2.50 | 10.31 | 10.31 | 80.97 | 107.18 | 0.6414 | 3.38 | 1.87 | 8,905,504.00 | 8.60 | 6.04 | 10.41 | 7.54 | 50.76 | 46.33 | 13.42 | 9.45 | 3.86 | 8.37 | 0.043 | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Morepen Laboratories Ltd | 17.55bn | 986.27m | 21.65bn | 1.81k | 21.89 | 1.81 | 15.34 | 1.23 | 1.80 | 1.80 | 32.16 | 21.83 | 1.06 | 4.24 | 6.12 | 9,677,225.00 | 6.03 | 8.14 | 8.20 | 12.81 | 33.02 | 31.83 | 5.67 | 5.91 | 1.65 | 6.43 | 0.1169 | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Hikal Ltd | 16.99bn | 101.00m | 22.62bn | 2.06k | 223.28 | 1.89 | 14.00 | 1.33 | 0.8216 | 0.8216 | 137.81 | 96.86 | 0.7065 | 2.01 | 4.59 | 8,239,573.00 | 0.42 | 4.78 | 0.6016 | 7.00 | 55.49 | 48.00 | 0.5945 | 5.71 | 0.5418 | 1.11 | 0.3639 | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Panacea Biotec Ltd | 6.04bn | -72.40m | 22.70bn | 1.29k | -- | 2.75 | 86.51 | 3.76 | -1.18 | -1.18 | 98.44 | 134.92 | 0.4836 | 1.38 | 8.67 | 4,681,039.00 | -0.6085 | 13.08 | -0.8291 | 19.61 | 58.47 | 48.06 | -1.26 | 30.99 | 0.9785 | -14.33 | 0.0271 | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 21.70bn | 1.16bn | 22.95bn | 2.89k | 19.80 | 1.31 | 11.90 | 1.06 | 3.95 | 3.95 | 73.97 | 59.66 | 0.9278 | 3.77 | 4.39 | 7,507,091.00 | 4.95 | 10.26 | 6.48 | 13.42 | 34.01 | 32.57 | 5.34 | 9.33 | 1.32 | 9.37 | 0.0832 | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 27.91bn | 3.33k | 9.48 | -- | 6.66 | 1.26 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| SMS Pharmaceuticals Ltd | 8.60bn | 843.60m | 29.99bn | 1.47k | 33.05 | 4.11 | 25.39 | 3.49 | 9.69 | 9.69 | 98.93 | 77.88 | 0.7134 | 1.82 | 3.96 | 5,850,513.00 | 6.72 | 5.58 | 9.76 | 7.66 | 33.05 | 33.78 | 9.42 | 8.05 | 0.916 | 5.98 | 0.3078 | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
Data as of Feb 10 2026. Currency figures normalised to Morepen Laboratories Ltd's reporting currency: Indian Rupee INR
1.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 6.68m | 1.22% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 1.18m | 0.22% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 523.99k | 0.10% |
| DFA Australia Ltd.as of 31 Dec 2025 | 116.66k | 0.02% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 18.14k | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 11.18k | 0.00% |
| Bandhan AMC Ltd.as of 31 Dec 2025 | 4.45k | 0.00% |
| Jennison Associates LLCas of 30 Sep 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
